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Summary.-C3H/He and CBA/T6T6 mice which share the H2k haplotype were com-
pared for their capacity to survive challenges with the C3H-derived fibrosarcoma
BP8. It was found:
(1) The tumour grows at the same ratewiththe samemediansurvivaltimeinmatched
groups of non-immunized mice from both strains after i.p. injection of tumour cells.
(2) Cyclophosphamide (Cyclo) at 10 mg/kg will cure CBA mice which have received
i.p. injections of 107 BP8, but this dose, and more intensive treatment with this drug,
fails to cure C3H mice.
(3) Injecting 125IUdR-labelled tumour cells and counting 125I loss by whole-mouse
counting shows that the cytotoxic effect ofCyclo against BP8 is similar in the2 mouse
strains.
(4) Cyclo itself does not cure CBA mice, for viable tumour cells are recoverable from
the peritoneal cavity 10 days after CBA mice have received 107 BP8 followed by 10 mg/
kg Cyclo.
(5) CBA mice cured of BP8 ascites by Cyclo treatment will reject further i.p. inocula of
BP8.
(6) The strength of immunity induced by irradiated BP8 cells was directly related to
the length of exposure to this antigen. An important aspect of Cyclo treatment is that
it prolongs the period during which immunity may develop.
(7) Immunization of CBA mice with heavily irradiated BP8, with or without Cyclo,
failed to show that Cyclo depressed the capacity of CBA mice to develop cytotoxic
immunity. There was some indication that animals immunized with irradiated cells
plus drug did better than those with irradiated cells alone.
(8) A single injection of irradiated BP8 cells into CBA mice induced weak cytotoxic
immunity, as assessed by destruction of a subsequent challenge with BP8, but these
mice died from tumour more rapidly than non-immunized controls. It is suggested
from these data that immunological enhancement may not always be due to blocking
of cytotoxic immunity.
THERE ARE NOW a number ofstudies on cytotoxic immunity. There are several
the combined effects of anti-tumour im- ways in which synergy between drug
munity and cytotoxic drugs (Mihich, treatment and immunity could occur, for
1969; Currie and Bagshawe, 1970; Moore example: (1) the drug may reduce the
and Williams, 1973; Amiel and Berardet, tumour load so that weak cytotoxic im-
1974; Pearson et al., 1974; Gotohda et al., munity can cope with the small residue of
1974; Fisher et at., 1975). However, in tumour cells; (2) drugs may actually
some instances it has been difficult to potentiate cytotoxic immunity by in-
distinguish the cytotoxic effect of the terfering with regulatory mechanisms
drug on the tumour from the effect of (Askenase et al., 1975; Otterness and
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Chang, 1976); and (3) delay in tumour
progression induced by the drug may allow
time for the development of protective
immunity.
We have explored these possible
mechanisms for synergy between anti-
tumour immunity and cytotoxic drugs,
using the weakly immunogenic C3H-
derived fibrosarcoma BP8 in syngeneic
mice and in CBA mice which share the
H2k haplotype. By using tumour cells
labelled with [1251] 5-iodo-2'-deoxyuridine
(125IUdR) we have been able to study the
relative contributions of drug treatment
and immunity in some detail. This tech-
nique was developed by Hughes et al.
(1964). IUdR is a thymidine analogue and
it is stably incorporated into the DNA of
cells. The label is only released when a
labelled cell dies. If the cell divides the
label is shared between the daughter cells.
The 1251 is excreted as iodide and,
provided any thyroid uptake is blocked by
giving cold iodide, the rate of loss of 1251
is a good measure of cell survival. Hofer et
al. (1970) used thistechniqueformeasuring
the cytotoxic effect of drugs in vivo, and
more recently the method has been used to
study cytotoxic immunity in vivo against
tumours (Porteous and Munro, 1972;
Chassoux et al., 1977).
MATERIALS AND METHODS
Animals.-C3H/He and CBA/T6T6 mice
were originally obtained from the MRC
Laboratory Animals Centre (Carshalton).
They were bred in our department by brother-
sister mating. Both strains have the haplo-
type H2k and sharetheThyl 2 antigen. Female
mice were used when 3-4 months old and
,-,25 g in weight. Potassium iodide (0-1%)
was given to mice in their drinking water,
from 2 days before the injection of 125IUdR-
labelled tumour cells, to prevent thyroid
incorporation of released 125lodide.
Tumour.-BP8 is a fibrosarcoma line
derived by Craigie in 1943 from a C3H mouse
treated with benzopyrene. It is maintained in
our laboratory in ascitic form by weekly i.p.
passage of 105 cells in our C3H mice.
Harvesting cellsfrom the peritoneal cavity.-
Animals were killed by cervical dislocation.
Heparinized Minimum Essential Medium
(MEM) was injected i.p. The cell-containing
medium was recovered through an abdominal
incision with a Pasteur pipette. A second lot
of medium was then added to the peritoneal
cavity and the cell suspension recovered. Cells
were centrifuged and resuspended in MEM.
The cell concentration was adjusted to
107/ml for injection into test animals.
Labelling tumour cells-.The method is that
described by Porteous and Munro (1972). C3H
mice were injected i.p. with 106 BP8 cells.
Four days later they were given 4 i.p. in-
jections, each of 05 ,uCi of 125IUdR (Radio-
chemical Centre, Amersham, 25-35 Ci/mmol)
at 3 h intervals. Two days later, cells were
harvested from the peritoneal cavity as
described above.
As8sessment of tumour-cell destruction in
vivo.-The 1251 remaining in test mice was
monitored daily in a specially designed well-
type scintillation counter, startingf 1 h after
the injection of labelled cells.
The results are expressed as the percent of
initial counts, after correction for radioactive
decay, based on the measurement of a
standard. Counts are plotted as geometric
means±one standard deviation.
Chemotherapy.-Cyclophosphamide (En-
doxana-WB Pharmaceuticals Ltd., Brack-
nell) (Cyclo) was injected i.v. in 01 ml into
the retro-orbital sinus of mice under ether
anaesthetic.
Drug was injected 1 h after the labelled
cells.
Irradiation.-Cell suspensions were
adjusted to 107/ml in heparinized MEM.
They were irradiated from a cobalt source at a
calculated rate of 100 rad/min for 12 min.
The cells were injected within 2 h of
irradiation.
RESULTS
The intraperitoneal growth rate of BP8 and
its modification by cyclophosphamide in
CBA compared with C3H mice
BP8 can be grown as an ascites tumour
and can be serially passaged in CBA as well
as in C3H mice. Formal comparison of the
i.p. growth rate of this tumour line has
failed to show any difference between the
2 strains (Table I). In contrast, survival
after Cyclo treatment is markedly different
between CBA and C3H mice previously
212CYCLOPHOSPHAMIDE THERAPY AND IMMUNITY AGAINST MOUSE TUMOUR 213
TABLE I. Median survival times of CBA
and C3H mice injected i.p. with BP8
Median survival times (days).
Number of mice in group
in brackets.
No. of BP8 cells
and timing
107 i.p. Day 0
5x 103 i.p. Day 0
5 x 106 i.p. Day 5
C3H
14 (4+4)
20 (4+6)
CBA
14 (5+6)
20 (4+5)
Four experiments where survival times were
directly compared between C3H and CBA mice. The
BP8 used in each experiment were prepared as a
single batch for injection into both strains of mice.
injected i.p. with BP8. Ten mg/kg of i.v.
Cyclo 1 h after an i.p. injection of 107
BP8 prevented 10/11 CBA mice from
developing fatal ascites tumour. However,
none of a range of doses of Cyclo to C3H
mice after injection of 107 BP8 stopped
death from the tumour (Table II). It will
be seen that 10 mg/kg of i.v. Cyclo
produced as great an increase in survival
time as larger or multiple doses of drug.
This observation is reflected in the rate
of tumour-cell destruction by drug, as
assessed by loss of 1251 from mice injected
with IUdR-labelled tumour cells (Fig. 1).
Theincreaseinsurvivalachievedin these
experiments was not improved when
tumour was given as a small inoculum of
5 x 103 tumour cells, and 10 mg/kg of
Cyclo was given 5 days later. After 5 days,
5x 106 tumour cells were recoverable
from the peritoneal cavity. Five x 106
125IUdR-labelled BP8 were given 1 h
before the drug, to allow its cytotoxic
effect to be followed.
Is the cytotoxic effect ofcyclophosphamide on
BP8 similar in CBA and C3H mice?
It was possible that Cyclo might have
been converted to active metabolites more
efficiently in CBA than in C3H mice. To
assess the relative cytotoxicity ofthis drug
on the tumour in these 2 strains, the rate
of 1251 excretion from mice injected with
125IUdR-labelled BP8 was assessed. Table
III shows 2 experiments in which 10 mg/kg
Cyclo was given i.v. to matched groups of
CBA and C3H mice previously injected
with labelled tumour. There was little
obvious difference between the strains in
the cytotoxic effect of the drug, when
assessed in this way. However, mice given
an initial small inoculation of BP8 5 days
before Cyclo did show more rapid loss of
isotope than those given 107 tumour cells
1 h before the drug. The reason for this has
not been investigated.
Does cyclophosphamide totally eliminate
tumourfrom CBA mice?
To answer this question the peritoneal
cavities of 4 CBA mice were washed out 10
days after Cyclo treatment, when no free
drug would be remaining. These mice had
previously been treated as in Experiment
1, Table III. The washings from each
mouse were injectedi.p. into anon-immune
CBA mouse. All the recipient mice
TABLE II. Effect of Cyclo on survival of C3H mice previously injected i.p. with BP8
Nature of BP8
injection (i.p.)
107 cellst Day 0
3 x 105 cells i.p. Day 0
5 x 106 cellst Day 5
Schedule of Cyclo
administration (i.v.)
No drug
2 mg/kg Day 0
5 mg/kg Day 0
10 mg/kg Day 0
10 mg/kg Days 0, 2, 4, 6, 8
20 mg/kg Days 0, 2
No drug
10 mg/kg Day 5
No. of mice
11
4
4
10
5
4
10
12
Median survival
(days)
14
15
22*
26*
24*
23*
21
31*
When they were given on the same day, the drug was given 1-2 h after the tumour cells.
* Significant prolongation of life (P<0 05, Willcoxon Rank sum test) compared with untreated controls
injected with the same schedule of BP8. All mice died with fatal ascites.
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FIG. 1.-125I excretion from C3H mice injected i.p. with 107 125JUdR-labelled BP8 and treated
with different schedules of Cyclo. * 0 =untreated controls. A A =2 mg/kg Cyclo Day
0. * *=5 mg/kg Cyclo Day 0. r- [=10 mg/kg Cyclo Day 0. 0 0=20 mg/kg
Cyclo Days 0 and 2. Results expressed as geometric mean of groups. For numbers in groups
see Table II.
TABLE Ill.-Comparison of the toxic effect of Cyclo on BP8 in C3H and CBA mice
as assessed by release of 125Ifrom IUdR-labelled tumour cells
Exp. 1. 6 mice in each group given 3 x 105 BP8 i.p. Day 0; 5 x 106 IUdR-labelled BP8 i.p. Day 5;
10 mg/kg Cyclo i.v. Day 5
Day 6 7 8 9 10 11 12 13
CBA - 61(+0 78) 26(±1-08) 11(+0O78) 6(+0 48) 4(±0 48) 3(±0-00) 3(A0 30)
C3H 54(±0 70) 26(±0 60) 17(±0 84) 9(±0 48) 5(±0 30) 3(±0 00) 2(±0 30)
Exp. 2. 4 mice in each group given 107 IUdR-labelled BP8 i.p. Day 0 and 10 mg/kg Cyclo i.v. Day 0
+1 h
Day
CBA
C3H
1 2 3 4 5 6 7 8
98(±0 00) 91(±0-30) 79(±0.00) 45(±0 95) 15(±0-95) 15(±0-30) 11(+0*00) 8(±0 30)
88(+0.48) 81(±0-30) 69(±0.48) 41(±0-95) 16(±0-78) 14(±0-60) 8(A0.48) 6(40 00)
Results are shown as the geometric mean of the % of injected 1251 retained on each day (±logio s.d.). The
% 125I retained in the 2 strains of mice was compared each day by 2-way t test on log values. No significant
difference was seen for any pair of values in Exp. 1, and only in the first 3 days in Exp. 2 was the difference
significant (P<0 05).
developed ascites and died with a median experiment that Cyclo alone, given in this
survival of 18 days after injection. This way, does not eliminate tumour.
equals the median survival after injection
of ...,105 tumour cells. None of 4 control Do CBA mice given i.p. BP8 and treated
mice without peritoneal aspiration, but with cyclophosphamide develop anti-tumour
who had received tumour and drug, died immunity?
with tumour. We conclude from this CBA mice given a primary i.p. injectionCYCLOPHOSPHAMIDE THERAPY AND IMMUNITY AGAINST MOUSE TUMOUR 215
DAYS AFTER PRIMARY INJECTION
FIG. 2.-The development of cytotoxic immunity against BP8 in CBA mice cured of BP8 ascites by
Cyclo 12 CBA mice were injected i.p. on Day 0 with 107 125IUdR-labelled BP8. 1 h later, 6 ofthese
(0- -0) received 10 mg/kg ofCyclo i.v. * 0* =the mice not given drugs. The untreated group
died with a median survival of 14 days. The treated group were alive and free ofascites on Day 30,
when they receive a second dose of 107 125IUdR-labelled BP8 i.p. 0-- 0-=the 1251 excretion from
these challenged mice. 0- 0=6 control untreated mice also injected with 107 BP8 on Day 30.
All the original Cyclo-treated mice were alive 6 months later, while the second control group
followed the typical pattern by developing fatal ascites. The results are plotted as geometric mean
±s.d.
of BP8 and treated with Cyclo as in
Table III (both protocols) were later
challenged i.p. with 107 BP8. A total of
15 mice in 2 experiments were re-
challenged; 9 at 42 days after Cyclo and 6
at 30 days after the drug. All these mice
successfully rejected the challenge (Fig. 2).
What is the effect of cyclophosphamide on
the induction of immunity against BP8 in
CBA mice?
To investigate this question, CBA mice
were immunized with an i.p. injection of
107 irradiated (12,000 rad) BP8 cells.
Half the mice were given i.v. Cyclo
10 mg/kg 1 h later. After 28 days, all mice
were challenged with 107 125IUdR-labelled
but non-irradiated BP8. Table IV shows
that both groups of immunized mice lost
1251 significantly more rapidly than non-
immunized controls (complete clearance
curves are shown for comparable groups in
Fig. 3). However, despite this, all mice
died from tumour. The mice receiving
irradiated tumour cells but no drug died
sooner than controls, or mice receiving
irradiated tumour cells plus Cyclo. The
reason for this enhancement of tumour
progression has not been further investi-
gated. These experiments indicate that in
this situation Cyclo (1) does not prevent
the development of cytotoxic immunity
as assessed by 125J release from l25IUdR-
labelled tumour cells; (2) prevents the
induction of enhanced tumour growth
seen after a single injection of irradiated
tumour cells.
Doesprolonged exposure to antigenfacilitate
the development ofanti-tumour immunity?
There is clearly a marked difference
between the immunizing capacity of
irradiated and unirradiated tumour cells in
this system where mice are treated with
Cyclo. We next investigated the possi-
bility that this difference was due to
differences in the exposure time to antigen
resulting from the limited viability of
irradiated BP8. We assessed the survival
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TABLE IV.-Effect of Cyclo on the induction ofimmunity against BP8 in CBA mice
by i.p. immunization with irradiated BP8
Drug and immunization
schedule
Irradiated cells+drug
Irradiated cells only
No immunization, no drug
Median survival
Exp. 1 Exp. 2
12.5 (8) 13.5 (8)
10.5 (8) 11.5 (8)
12.0 (4) 14-0 (4)
Geometric mean % 125I excretion Day 9
after live-cell challenge
Drugandimmunization~~~~~~~~~~A
Exp. 1
22
17
60
Exp. 2
17
16
40
Immunization was with 107 irradiated cells (12,000 rad). Drug was given 1 h later. After 28 days all mice
were challenged with 107 125IUdR-labelled tumour cells. The survival of the group receiving irradiated cells
without drugs was less than that of non-immune controls (P<0*05) and mice receiving irradiated cells+
drugs P<0 -01 (2-tailed Wilcoxon rank-sum test on pooled results of the 2 experiments). The 125I excretion
was greater in the two immunized groups than the non-immune group in both experiments on Days 3-9 after
challenge (P<0-01; two-tailed t test on log percent 125I retained).
DAYS AFTER PRIMARY INJECTION
2 4
FIG. 3.-The effect ofimmunizing OBA mice with heavily irradiated cells i.p. On Day 0 12 mice were
given 107 125IUdR-labelled heavily irradiated BP8. The rate of 125I excretion from these mice is
shown by the line M. 6 ofthese mice received further injections ofirradiated BP8 onDays 14
and 21. All 12 mice and 6 non-immunized controls were challenged i.p. with 107 live 125IUdR-
labelled BP8 on Day 28. M .... - =non-immunized controls. 0 --- - =mice receiving a single
immunization with irradiated BP8. *0*=micereceiving 3 immunizations with irradiated BP8.
Results are expressed as geometric mean ±s.d. for the injections on Day 0. Plots ofindividual mice
are shown for injections on Day 28.
of irradiated BP8 by pre-labelling the
tumour cells with 125IUdR before injection
into CBA mice (Fig. 3). Whilst cells
irradiated in this way do not grow to form
ascites, their rate of death is considerably
less rapid than that of cells killed by other
techniques such as freezing and thawing,
in which over 95% of the isotope is lost
by 48 h (Falcao et al., 1977). Next, groups
of mice given a single dose of irradiated
cells were compared with mice given 3
immunizations at 0, 14 and 21 days, for
their capacity to resist a challenge of 107
unirradiated but 125IUdR-labelled BP8 on
Day 28. Fig. 3 shows that repeated
exposure to irradiated tumour does im-
prove cytotoxic immunity as assessed by
125I clearance, over that seenwhen a single
injection ofirradiated cells wasgiven. Also,
4/6 mice receiving 3 immunizations, re-
jected the tumour challenge, although 2 of
them, who showed slower 125I loss,
developed ascites and died on Days 14 and
21 respectively. As with the previous
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experiment, none of the mice receiving a
single immunization with irradiated cells
survived the live-tumour challenge.
DISCUSSION
The use of125IUdR in these experiments
has allowed us to studv the relative con-
tributions of Cyclo and host immunity to
the elimination of this potentially lethal
ascites tumour. The wash-out studies in
Cyclo-treated CBA mice showed that the
recoverable tumour load 10 days after
treatment was 105 cells. However,
Cyclo does delay the build up oftumour to
the level of overt ascites by up to 2 weeks.
It may be that this delay alone is sufficient
to allow protective immunity to develop.
However, the tentative conclusion which
can be drawn from the experiments in
which mice were immunized with irradi-
ated cells is that Cyclo may actually
facilitate the expression of immunity. The
idea that this drug can produce such an
effect is by no means new. Otterness and
Chang (1976) showed an increase in T-cell
cytotoxicity against a syngeneic tumour
in mice after a single dose of 10 mg/kg of
Cyclo, given at the same time as tumour
cells. However, different timings and doses
of drug reduced T-cell cytotoxicity.
Askenase et al. (1975) showed an increase
in delayed hypersensitivity reactions to
sheep red cells when mice were tested 10
days after receiving 20 mg/kg of Cyclo.
These mice had been given a primary
immunization the day after the drug.
Finerty and Krehl (1976) also showed
potentiation of immunity in mice against
plasmodium following Cyclo treatment. On
the other hand, there are also many
references in which Cyclo has been shown
to be an active immunosuppressive agent
(Berenbaum, 1975).
If Cyclo is potentiating immunity, a
number of possible mechanisms come to
mind. Firstly the potentiation may simply
be due to the drug preserving antigen in a
non-lethal form for many days within the
animal. Theincreasedimmunity seen when
3 immunizations with heavily irradiated
cells are used, comparedwithone, indicates
that length of antigen exposure is an
important factor, and this alone may
provide an adequate explanation for the
good immunity seen after Cyclo. It is also
possible that the drugs may modify the
antigenicity ofthe tumour cells to increase
their immunogenicity. Such an effect has
been recorded for tumour cells exposed to
ionizing irradiation (Haddow and
Alexander, 1964; Mathe et al., 1969;
Bomford, 1975; McBurney, 1976). Alterna-
tive mechanisms of potentiation include
the modification of antigen processing or
the inhibition ofhomoeostatic mechanisms
(Ramshaw et al., 1976).
CBA mice given a single i.p. immuniz-
ation with heavily irradiated BP8 show
clear evidenceofweakcytotoxicimmunity,
as assessed by 1251 loss, against a sub-
sequent challenge of live BP8 cells (Table
IV). However, these mice die significantly
more rapidly from tumour than non-
immunized mice do. This paradoxical
result poses a number of interesting
questions. Firstly does this finding mean
that increased 1251 loss in this instance is
not reflecting truetumour-cell destruction?
There are many reasons for delay in 1251
loss from mice following destruction of
125IUdR-labelled tumour cells, including
phagocytosis of dead cell debris, uptake of
iodide by the thyroid, and impaired renal
excretion. However, it is difficult to think
of reasons for falsely high rates of 1251
loss, other than injection of tumour into
the gut. This gives a far more rapid loss of
isotope than that seen in the immunized
group of mice. In interpreting these data,
one has to remember that BP8 is a rapidly
dividing tumour. Mean cell-cycle times
during the initial exponential growth
phase after i.p. injection are around 12-
14 h. Consequently, whilst 20% 1251
excretion during the first day after the
injection of 107 125IUdR-labelled BP8,
reflects death of 2x 106 cells, the same
percentage loss 2 days later might reflect
the death of 2 x 107 cells. The tumour-cell
destruction rates in the mice immunized
with a single injection of irradiated BP8218 D. M. CHASSOUX, F. M. GOTCH AND I. C. M. MACLENNAN
(Fig. 3) are never great enough to counter
the exponential growth potential of BP8.
Consequently, cure by this level of cyto-
toxic immunity would not be expected.
Despite these arguments one still has to
explain the more rapid death in mice
immunized with irradiated cells than in
controls. The way in which this tumour
kills the host is not fully clear. In common
with other experimental tumours, ex-
ponential growth does not continue in-
definitely. Here the maximum number of
tumour cells recoverable from the peri-
toneal cavity is between 5 and 8 x 108
cells, and before death this number often
falls. It would seem reasonable to postulate
that the rapid death in mice immunized in
this way is related to alterations in the
poorly understood events occurring when
net tumour growth has effectively stopped.
Without the use of 125IUdR studies the
reduced survival time associated with
immunization might have been attributed
to blocking of cytotoxic immunity. These
studies suggest that immunological en-
hancement in some instances may be
attributable to quite different mechanisms.
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